Loading...
•
Mar 31, 2024
Regeneron Q1 2024 Earnings Report
Reported a slight decrease in revenue but experienced growth in key products and pipeline advancements.
Key Takeaways
Regeneron reported first quarter 2024 financial results with a 1% decrease in total revenue to $3.145 billion. Excluding Ronapreve, revenues increased by 7%. The company saw significant growth in Dupixent and Libtayo sales, and the pipeline progressed with regulatory submissions and approvals.
Total revenues decreased by 1% to $3.145 billion, but increased 7% excluding Ronapreve.
Dupixent global net sales increased by 24% to $3.08 billion.
U.S. net sales for EYLEA HD and EYLEA were $1.40 billion, including $200 million from EYLEA HD.
Libtayo global net sales increased by 45% to $264 million.
Regeneron
Regeneron
Regeneron Revenue by Segment
Regeneron Revenue by Geographic Location
Revenue by Segment
Net Product Sales Revenue
CapyFin.comCollaboration Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
U.S. Net Product Sales Revenue
CapyFin.com Forward Guidance
Regeneron updated its full year 2024 financial guidance, reflecting the acquisition of 2seventy bio's pipeline.
Positive Outlook
- GAAP R&D expenses are now projected to be $4.920–$5.170 billion.
- Non-GAAP R&D expenses are projected to be $4.400–$4.600 billion.
- GAAP SG&A expenses are projected to be $2.940–$3.090 billion.
- Non-GAAP SG&A expenses are projected to be $2.550–$2.650 billion.
- GAAP effective tax rate is projected to be 7%-9%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income